世界の癌用PARP阻害剤市場2021-2026:リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他

LP Informationが発行した調査報告書(LPI21MY9616)
◆英語タイトル:Global PARP Inhibitors for Cancer Market Growth 2021-2026
◆商品コード:LPI21MY9616
◆発行会社(リサーチ会社):LP Information
◆発行日:2021年5月(※2024年版があります。お問い合わせください)
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

LPインフォメーション社の「癌用PARP阻害剤の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他など、用途別には、卵巣がん、乳がん、その他などにセグメント区分してまとめました。癌用PARP阻害剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・癌用PARP阻害剤の世界市場概要(サマリー)
・癌用PARP阻害剤の企業別販売量・売上
・癌用PARP阻害剤の企業別市場シェア
・癌用PARP阻害剤の世界市場規模 2016年-2021年:種類別(リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他)
・癌用PARP阻害剤の世界市場規模 2016年-2021年:用途別(卵巣がん、乳がん、その他)
・癌用PARP阻害剤の南北アメリカ市場規模(アメリカ、カナダ、メキシコなど)
・癌用PARP阻害剤のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・癌用PARP阻害剤のヨーロッパ市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・癌用PARP阻害剤の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・癌用PARP阻害剤市場の成長要因・課題・動向
・癌用PARP阻害剤の世界市場予測 2021年-2026年
・癌用PARP阻害剤の南北アメリカ市場予測(アメリカ、カナダ、メキシコなど)
・癌用PARP阻害剤のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・癌用PARP阻害剤のヨーロッパ市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・癌用PARP阻害剤の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・癌用PARP阻害剤の世界市場予測:種類別(リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他)
・癌用PARP阻害剤の世界市場予測:用途別(卵巣がん、乳がん、その他)
・主要企業分析
【レポートの概要】

According to this latest study, the 2021 growth of PARP Inhibitors for Cancer will have significant change from previous year. By the most conservative estimates of global PARP Inhibitors for Cancer market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the PARP Inhibitors for Cancer market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of PARP Inhibitors for Cancer market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Lynparza
Zejula
Rubraca
Talzenna
Other

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Ovarian Cancer
Breast Cancer
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global PARP Inhibitors for Cancer Consumption 2016-2026
2.1.2 PARP Inhibitors for Cancer Consumption CAGR by Region
2.2 PARP Inhibitors for Cancer Segment by Type
2.2.1 Lynparza
2.2.2 Zejula
2.2.3 Rubraca
2.2.4 Talzenna
2.2.5 Other
2.3 PARP Inhibitors for Cancer Sales by Type
2.3.1 Global PARP Inhibitors for Cancer Sales Market Share by Type (2016-2021)
2.3.2 Global PARP Inhibitors for Cancer Revenue and Market Share by Type (2016-2021)
2.3.3 Global PARP Inhibitors for Cancer Sale Price by Type (2016-2021)
2.4 PARP Inhibitors for Cancer Segment by Application
2.4.1 Ovarian Cancer
2.4.2 Breast Cancer
2.4.3 Other
2.5 PARP Inhibitors for Cancer Sales by Application
2.5.1 Global PARP Inhibitors for Cancer Sale Market Share by Application (2016-2021)
2.5.2 Global PARP Inhibitors for Cancer Revenue and Market Share by Application (2016-2021)
2.5.3 Global PARP Inhibitors for Cancer Sale Price by Application (2016-2021)

3 Global PARP Inhibitors for Cancer by Company
3.1 Global PARP Inhibitors for Cancer Sales Market Share by Company
3.1.1 Global PARP Inhibitors for Cancer Sales by Company (2019-2021)
3.1.2 Global PARP Inhibitors for Cancer Sales Market Share by Company (2019-2021)
3.2 Global PARP Inhibitors for Cancer Revenue Market Share by Company
3.2.1 Global PARP Inhibitors for Cancer Revenue by Company (2019-2021)
3.2.2 Global PARP Inhibitors for Cancer Revenue Market Share by Company (2019-2021)
3.3 Global PARP Inhibitors for Cancer Sale Price by Company
3.4 Global Manufacturers PARP Inhibitors for Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PARP Inhibitors for Cancer Product Location Distribution
3.4.2 Players PARP Inhibitors for Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 PARP Inhibitors for Cancer by Region
4.1 Global PARP Inhibitors for Cancer by Region
4.1.1 Global PARP Inhibitors for Cancer Sales by Region
4.1.2 Global PARP Inhibitors for Cancer Revenue by Region
4.2 Americas PARP Inhibitors for Cancer Sales Growth
4.3 APAC PARP Inhibitors for Cancer Sales Growth
4.4 Europe PARP Inhibitors for Cancer Sales Growth
4.5 Middle East & Africa PARP Inhibitors for Cancer Sales Growth

5 Americas
5.1 Americas PARP Inhibitors for Cancer Sales by Country
5.1.1 Americas PARP Inhibitors for Cancer Sales by Country (2016-2021)
5.1.2 Americas PARP Inhibitors for Cancer Revenue by Country (2016-2021)
5.2 Americas PARP Inhibitors for Cancer Sales by Type
5.3 Americas PARP Inhibitors for Cancer Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC PARP Inhibitors for Cancer Sales by Region
6.1.1 APAC PARP Inhibitors for Cancer Sales by Region (2016-2021)
6.1.2 APAC PARP Inhibitors for Cancer Revenue by Region (2016-2021)
6.2 APAC PARP Inhibitors for Cancer Sales by Type
6.3 APAC PARP Inhibitors for Cancer Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe PARP Inhibitors for Cancer by Country
7.1.1 Europe PARP Inhibitors for Cancer Sales by Country (2016-2021)
7.1.2 Europe PARP Inhibitors for Cancer Revenue by Country (2016-2021)
7.2 Europe PARP Inhibitors for Cancer Sales by Type
7.3 Europe PARP Inhibitors for Cancer Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa PARP Inhibitors for Cancer by Country
8.1.1 Middle East & Africa PARP Inhibitors for Cancer Sales by Country (2016-2021)
8.1.2 Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2016-2021)
8.2 Middle East & Africa PARP Inhibitors for Cancer Sales by Type
8.3 Middle East & Africa PARP Inhibitors for Cancer Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 PARP Inhibitors for Cancer Distributors
10.3 PARP Inhibitors for Cancer Customer

11 Global PARP Inhibitors for Cancer Market Forecast
11.1 Global PARP Inhibitors for Cancer Forecast by Region
11.1.1 Global PARP Inhibitors for Cancer Forecast by Regions (2021-2026)
11.2.2 Global PARP Inhibitors for Cancer Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global PARP Inhibitors for Cancer Forecast by Type
11.7 Global PARP Inhibitors for Cancer Forecast by Application

12 Key Players Analysis
12.1 AstraZeneca
12.1.1 AstraZeneca Company Information
12.1.2 AstraZeneca PARP Inhibitors for Cancer Product Offered
12.1.3 AstraZeneca PARP Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 AstraZeneca Main Business Overview
12.1.5 AstraZeneca Latest Developments
12.2 Tesaro
12.2.1 Tesaro Company Information
12.2.2 Tesaro PARP Inhibitors for Cancer Product Offered
12.2.3 Tesaro PARP Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Tesaro Main Business Overview
12.2.5 Tesaro Latest Developments
12.3 Merck & Co
12.3.1 Merck & Co Company Information
12.3.2 Merck & Co PARP Inhibitors for Cancer Product Offered
12.3.3 Merck & Co PARP Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Merck & Co Main Business Overview
12.3.5 Merck & Co Latest Developments
12.4 Clovis Oncology
12.4.1 Clovis Oncology Company Information
12.4.2 Clovis Oncology PARP Inhibitors for Cancer Product Offered
12.4.3 Clovis Oncology PARP Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Clovis Oncology Main Business Overview
12.4.5 Clovis Oncology Latest Developments
12.5 Pfizer
12.5.1 Pfizer Company Information
12.5.2 Pfizer PARP Inhibitors for Cancer Product Offered
12.5.3 Pfizer PARP Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Pfizer Main Business Overview
12.5.5 Pfizer Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. PARP Inhibitors for Cancer Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Lynparza
Table 3. Major Players of Zejula
Table 4. Major Players of Rubraca
Table 5. Major Players of Talzenna
Table 6. Major Players of Other
Table 7. Global PARP Inhibitors for Cancer Sales by Type (2016-2021) & (K Units)
Table 8. Global PARP Inhibitors for Cancer Sales Market Share by Type (2016-2021)
Table 9. Global PARP Inhibitors for Cancer Revenue by Type (2016-2021) & ($ million)
Table 10. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2016-2021)
Table 11. Global PARP Inhibitors for Cancer Sale Price by Type (2016-2021)
Table 12. Global PARP Inhibitors for Cancer Sales by Application (2016-2021) & (K Units)
Table 13. Global PARP Inhibitors for Cancer Sales Market Share by Application (2016-2021)
Table 14. Global PARP Inhibitors for Cancer Value by Application (2016-2021)
Table 15. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2016-2021)
Table 16. Global PARP Inhibitors for Cancer Sale Price by Application (2016-2021)
Table 17. Global PARP Inhibitors for Cancer Sales by Company (2019-2021) & (K Units)
Table 18. Global PARP Inhibitors for Cancer Sales Market Share by Company (2019-2021)
Table 19. Global PARP Inhibitors for Cancer Revenue by Company (2019-2021) ($ Millions)
Table 20. Global PARP Inhibitors for Cancer Revenue Market Share by Company (2019-2021)
Table 21. Global PARP Inhibitors for Cancer Sale Price by Company (2019-2021)
Table 22. Key Manufacturers PARP Inhibitors for Cancer Producing Area Distribution and Sales Area
Table 23. Players PARP Inhibitors for Cancer Products Offered
Table 24. PARP Inhibitors for Cancer Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global PARP Inhibitors for Cancer Sales by Region (2016-2021) (K Units)
Table 28. Global PARP Inhibitors for Cancer Sales Market Share by Region (2016-2021)
Table 29. Global PARP Inhibitors for Cancer Revenue by Region (2016-2021) & ($ Millions)
Table 30. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2016-2021)
Table 31. Americas PARP Inhibitors for Cancer Sales by Country (2016-2021) & (K Units)
Table 32. Americas PARP Inhibitors for Cancer Sales Market Share by Country (2016-2021)
Table 33. Americas PARP Inhibitors for Cancer Revenue by Country (2016-2021) & ($ Millions)
Table 34. Americas PARP Inhibitors for Cancer Revenue Market Share by Country (2016-2021)
Table 35. Americas PARP Inhibitors for Cancer Sales by Type (2016-2021) & (K Units)
Table 36. Americas PARP Inhibitors for Cancer Sales Market Share by Type (2016-2021)
Table 37. Americas PARP Inhibitors for Cancer Sales by Application (2016-2021) & (K Units)
Table 38. Americas PARP Inhibitors for Cancer Sales Market Share by Application (2016-2021)
Table 39. APAC PARP Inhibitors for Cancer Sales by Region (2016-2021) & (K Units)
Table 40. APAC PARP Inhibitors for Cancer Sales Market Share by Region (2016-2021)
Table 41. APAC PARP Inhibitors for Cancer Revenue by Region (2016-2021) & ($ Millions)
Table 42. APAC PARP Inhibitors for Cancer Revenue Market Share by Region (2016-2021)
Table 43. APAC PARP Inhibitors for Cancer Sales by Type (2016-2021) & (K Units)
Table 44. APAC PARP Inhibitors for Cancer Sales Market Share by Type (2016-2021)
Table 45. APAC PARP Inhibitors for Cancer Sales by Application (2016-2021) & (K Units)
Table 46. APAC PARP Inhibitors for Cancer Sales Market Share by Application (2016-2021)
Table 47. Europe PARP Inhibitors for Cancer Sales by Country (2016-2021) & (K Units)
Table 48. Europe PARP Inhibitors for Cancer Sales Market Share by Country (2016-2021)
Table 49. Europe PARP Inhibitors for Cancer Revenue by Country (2016-2021) & ($ Millions)
Table 50. Europe PARP Inhibitors for Cancer Revenue Market Share by Country (2016-2021)
Table 51. Europe PARP Inhibitors for Cancer Sales by Type (2016-2021) & (K Units)
Table 52. Europe PARP Inhibitors for Cancer Sales Market Share by Type (2016-2021)
Table 53. Europe PARP Inhibitors for Cancer Sales by Application (2016-2021) & (K Units)
Table 54. Europe PARP Inhibitors for Cancer Sales Market Share by Application (2016-2021)
Table 55. Middle East & Africa PARP Inhibitors for Cancer Sales by Country (2016-2021) & (K Units)
Table 56. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Country (2016-2021)
Table 57. Middle East & Africa PARP Inhibitors for Cancer Revenue by Country (2016-2021) & ($ Millions)
Table 58. Middle East & Africa PARP Inhibitors for Cancer Revenue Market Share by Country (2016-2021)
Table 59. Middle East & Africa PARP Inhibitors for Cancer Sales by Type (2016-2021) & (K Units)
Table 60. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Type (2016-2021)
Table 61. Middle East & Africa PARP Inhibitors for Cancer Sales by Application (2016-2021) & (K Units)
Table 62. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Application (2016-2021)
Table 63. Key and Potential Regions of PARP Inhibitors for Cancer
Table 64. Key Application and Potential Industries of PARP Inhibitors for Cancer
Table 65. Key Challenges of PARP Inhibitors for Cancer
Table 66. Key Trends of PARP Inhibitors for Cancer
Table 67. PARP Inhibitors for Cancer Distributors List
Table 68. PARP Inhibitors for Cancer Customer List
Table 69. Global PARP Inhibitors for Cancer Sales Forecast by Region (2021-2026) & (K Units)
Table 70. Global PARP Inhibitors for Cancer Consumption Market Forecast by Region
Table 71. Global PARP Inhibitors for Cancer Revenue Forecast by Region (2021-2026) & ($ millions)
Table 72. Global PARP Inhibitors for Cancer Revenue Market Share Forecast by Region (2021-2026)
Table 73. Americas PARP Inhibitors for Cancer Sales Forecast by Country (2021-2026) & (K Units)
Table 74. Americas PARP Inhibitors for Cancer Revenue Forecast by Country (2021-2026) & ($ millions)
Table 75. APAC PARP Inhibitors for Cancer Sales Forecast by Region (2021-2026) & (K Units)
Table 76. APAC PARP Inhibitors for Cancer Revenue Forecast by Region (2021-2026) & ($ millions)
Table 77. Europe PARP Inhibitors for Cancer Sales Forecast by Country (2021-2026) & (K Units)
Table 78. Europe PARP Inhibitors for Cancer Revenue Forecast by Country (2021-2026) & ($ millions)
Table 79. Middle East & Africa PARP Inhibitors for Cancer Sales Forecast by Country (2021-2026) & (K Units)
Table 80. Middle East & Africa PARP Inhibitors for Cancer Revenue Forecast by Country (2021-2026) & ($ millions)
Table 81. Global PARP Inhibitors for Cancer Sales Forecast by Type (2021-2026) & (K Units)
Table 82. Global PARP Inhibitors for Cancer Sales Market Share Forecast by Type (2021-2026)
Table 83. Global PARP Inhibitors for Cancer Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 84. Global PARP Inhibitors for Cancer Revenue Market Share Forecast by Type (2021-2026)
Table 85. Global PARP Inhibitors for Cancer Sales Forecast by Application (2021-2026) & (K Units)
Table 86. Global PARP Inhibitors for Cancer Sales Market Share Forecast by Application (2021-2026)
Table 87. Global PARP Inhibitors for Cancer Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 88. Global PARP Inhibitors for Cancer Revenue Market Share Forecast by Application (2021-2026)
Table 89. AstraZeneca Basic Information, PARP Inhibitors for Cancer Manufacturing Base, Sales Area and Its Competitors
Table 90. AstraZeneca PARP Inhibitors for Cancer Product Offered
Table 91. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 92. AstraZeneca Main Business
Table 93. AstraZeneca Latest Developments
Table 94. Tesaro Basic Information, PARP Inhibitors for Cancer Manufacturing Base, Sales Area and Its Competitors
Table 95. Tesaro PARP Inhibitors for Cancer Product Offered
Table 96. Tesaro PARP Inhibitors for Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 97. Tesaro Main Business
Table 98. Tesaro Latest Developments
Table 99. Merck & Co Basic Information, PARP Inhibitors for Cancer Manufacturing Base, Sales Area and Its Competitors
Table 100. Merck & Co PARP Inhibitors for Cancer Product Offered
Table 101. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 102. Merck & Co Main Business
Table 103. Merck & Co Latest Developments
Table 104. Clovis Oncology Basic Information, PARP Inhibitors for Cancer Manufacturing Base, Sales Area and Its Competitors
Table 105. Clovis Oncology PARP Inhibitors for Cancer Product Offered
Table 106. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 107. Clovis Oncology Main Business
Table 108. Clovis Oncology Latest Developments
Table 109. Pfizer Basic Information, PARP Inhibitors for Cancer Manufacturing Base, Sales Area and Its Competitors
Table 110. Pfizer PARP Inhibitors for Cancer Product Offered
Table 111. Pfizer PARP Inhibitors for Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 112. Pfizer Main Business
Table 113. Pfizer Latest Developments
List of Figures
Figure 1. Picture of PARP Inhibitors for Cancer
Figure 2. PARP Inhibitors for Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PARP Inhibitors for Cancer Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global PARP Inhibitors for Cancer Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. PARP Inhibitors for Cancer Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Lynparza
Figure 10. Product Picture of Zejula
Figure 11. Product Picture of Rubraca
Figure 12. Product Picture of Talzenna
Figure 13. Product Picture of Other
Figure 14. Global PARP Inhibitors for Cancer Sales Market Share by Type in 2020
Figure 15. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2016-2021)
Figure 16. PARP Inhibitors for Cancer Consumed in Ovarian Cancer
Figure 17. Global PARP Inhibitors for Cancer Market: Ovarian Cancer (2016-2021) & (K Units)
Figure 18. PARP Inhibitors for Cancer Consumed in Breast Cancer
Figure 19. Global PARP Inhibitors for Cancer Market: Breast Cancer (2016-2021) & (K Units)
Figure 20. PARP Inhibitors for Cancer Consumed in Other
Figure 21. Global PARP Inhibitors for Cancer Market: Other (2016-2021) & (K Units)
Figure 22. Global PARP Inhibitors for Cancer Sales Market Share by Application (2016-2021)
Figure 23. Global PARP Inhibitors for Cancer Revenue Market Share by Application in 2020
Figure 24. PARP Inhibitors for Cancer Revenue Market by Company in 2020 ($ Million)
Figure 25. Global PARP Inhibitors for Cancer Revenue Market Share by Company in 2020
Figure 26. Global PARP Inhibitors for Cancer Sales Market Share by Regions (2016-2021)
Figure 27. Global PARP Inhibitors for Cancer Revenue Market Share by Region in 2020
Figure 28. Americas PARP Inhibitors for Cancer Sales 2016-2021 (K Units)
Figure 29. Americas PARP Inhibitors for Cancer Revenue 2016-2021 ($ Millions)
Figure 30. APAC PARP Inhibitors for Cancer Sales 2016-2021 (K Units)
Figure 31. APAC PARP Inhibitors for Cancer Revenue 2016-2021 ($ Millions)
Figure 32. Europe PARP Inhibitors for Cancer Sales 2016-2021 (K Units)
Figure 33. Europe PARP Inhibitors for Cancer Revenue 2016-2021 ($ Millions)
Figure 34. Middle East & Africa PARP Inhibitors for Cancer Sales 2016-2021 (K Units)
Figure 35. Middle East & Africa PARP Inhibitors for Cancer Revenue 2016-2021 ($ Millions)
Figure 36. Americas PARP Inhibitors for Cancer Sales Market Share by Country in 2020
Figure 37. Americas PARP Inhibitors for Cancer Revenue Market Share by Country in 2020
Figure 38. Americas PARP Inhibitors for Cancer Sales Market Share by Type in 2020
Figure 39. Americas PARP Inhibitors for Cancer Sales Market Share by Application in 2020
Figure 40. United States PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 41. Canada PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 42. Mexico PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 43. Brazil PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 44. APAC PARP Inhibitors for Cancer Sales Market Share by Region in 2020
Figure 45. APAC PARP Inhibitors for Cancer Revenue Market Share by Regions in 2020
Figure 46. APAC PARP Inhibitors for Cancer Sales Market Share by Type in 2020
Figure 47. APAC PARP Inhibitors for Cancer Sales Market Share by Application in 2020
Figure 48. China PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 49. Japan PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 50. Korea PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 51. Southeast Asia PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 52. India PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 53. Australia PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 54. Europe PARP Inhibitors for Cancer Sales Market Share by Country in 2020
Figure 55. Europe PARP Inhibitors for Cancer Revenue Market Share by Country in 2020
Figure 56. Europe PARP Inhibitors for Cancer Sales Market Share by Type in 2020
Figure 57. Europe PARP Inhibitors for Cancer Sales Market Share by Application in 2020
Figure 58. Germany PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 59. France PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 60. UK PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 61. Italy PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 62. Russia PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 63. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Country in 2020
Figure 64. Middle East & Africa PARP Inhibitors for Cancer Revenue Market Share by Country in 2020
Figure 65. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Type in 2020
Figure 66. Middle East & Africa PARP Inhibitors for Cancer Sales Market Share by Application in 2020
Figure 67. Egypt PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 68. South Africa PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 69. Israel PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 70. Turkey PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 71. GCC Country PARP Inhibitors for Cancer Revenue Growth 2016-2021 ($ Millions)
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles


【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の癌用PARP阻害剤市場2021-2026:リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他(Global PARP Inhibitors for Cancer Market Growth 2021-2026)]についてメールでお問い合わせはこちらでお願いします。